Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | GCK | P35557 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12924661 | 0.79 | HCAR3 (0.36) | ALDH1A1ADORA2AADORA1MGLLACHE | |
| SCHEMBL784212 | 0.79 | ACHE (0.33) | ALDH1A1ADORA2AADORA1MGLLACHE | |
| SCHEMBL784347 | 0.78 | ADORA1 (0.40) | ALDH1A1LMNAADORA2AADORA1MGLL | |
| SCHEMBL2629297 | 0.76 | ALDH1A1 (0.38) | ALDH1A1LMNAKDM4ERIPK1MGLL | |
| SCHEMBL12410701 | 0.75 | BRD4 (0.36) | RIPK1MGLLACHE | |
| SCHEMBL12410700 | 0.75 | NOTUM (0.46) | ALDH1A1KDM4EMGLL | |
| SCHEMBL12777993 | 0.72 | POLB (0.40) | LMNAMGLL | |
| SCHEMBL12149907 | 0.72 | LMNA (0.30) | LMNA | |
| SCHEMBL22040162 | 0.71 | ADORA1 (0.45) | LMNAKDM4EADORA2AADORA1ADORA3 | |
| SCHEMBL12410998 | 0.71 | MGLL (0.33) | ALDH1A1KDM4EMGLLACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | ALDH1A1 269/4885LMNA 2528/4885KDM4E 3088/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | ALDH1A1 269/4885LMNA 2528/4885KDM4E 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.